NCT03665740 (MINER) is a Phase 2 clinical trial of Resveratrol in Gulf War Illness, sponsored by VISN 17 Center of Excellence.

Who is sponsoring NCT03665740?

NCT03665740 is sponsored by VISN 17 Center of Excellence.

What drugs are being tested in NCT03665740?

Interventions in NCT03665740: Resveratrol.

What condition does NCT03665740 study?

NCT03665740 studies Gulf War Illness.

Is NCT03665740 still recruiting?

NCT03665740 is currently status unknown. Last updated 11 September 2018.

Last reviewed 2018-09-11 · How we verify

NCT03665740: MINER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multimodal Investigation of the Neuroprotective Effects of Resveratrol (MINER)

Status unknown Phase 2 Last updated 11 September 2018

What this trial tests

Phase 2 trial testing Resveratrol in Gulf War Illness in 68 participants. Status unknown.

Timeline

1 August 2018

Primary endpoint
31 August 2022

31 August 2022

Quick facts

Lead sponsor	VISN 17 Center of Excellence
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	68
Start date	1 August 2018
Primary completion	31 August 2022
Estimated completion	31 August 2022
Sites	1 location across United States

Drugs / interventions tested

Resveratrol — full drug profile →

Conditions studied

Gulf War Illness — all drugs for Gulf War Illness →

Sponsor

VISN 17 Center of Excellence

Who can join

Adults 44 to 68, any sex, with Gulf War Illness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Since their return from military service in the 1990-1991 Gulf War, many Veterans have been affected by debilitating symptoms that are not easily explained. A leading hypothesis states that the combination of exposure to toxic chemicals and environmental stressors are responsible for a cluster of debilitating symptoms known as Gulf War Illness (GWI). Research has found that over-the-counter antioxidant supplements such as resveratrol may reverse the damage that causes these debilitating symptoms. Resveratrol is a nutrient found abundantly in the skin of red grapes that is known to have robust antioxidant and anti-inflammatory properties. The investigators predict that resveratrol treatment will improve memory issues, difficulties with thinking and mood problems in Veterans with GWI and that resveratrol will do so with minimal risk.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Human Sirtuin Regulators: The "Success" Stories.
Curry AM, White DS, Donu D, Cen Y. · · 2021 · cited 64× · PMID 34744791 · DOI 10.3389/fphys.2021.752117
Gulf War Illness: Mechanisms Underlying Brain Dysfunction and Promising Therapeutic Strategies.
Dickey B, Madhu LN, Shetty AK. · · 2021 · cited 54× · PMID 33164782 · DOI 10.1016/j.pharmthera.2020.107716
Phytochemicals in the treatment of inflammation-associated diseases: the journey from preclinical trials to clinical practice.
Nisar A, Jagtap S, Vyavahare S, Deshpande M, et al · · 2023 · cited 49× · PMID 37229273 · DOI 10.3389/fphar.2023.1177050

Verify or expand the search:

Other trials of Resveratrol

Trials testing the same drug.

NCT06250283 — Resveratrol for the Prevention of Bone Loss in Postmenopausal Women · NA · completed
NCT05808387 — The Effects of Resveratrol on Sirtuins and Apoptosis Biomarkers · NA · recruiting
NCT06131918 — Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy · Phase 2 · completed
NCT05653895 — Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS · NA · completed
NCT05410093 — Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency · NA · unknown

Other recruiting trials for Gulf War Illness

Currently open trials in the same condition.

NCT05820893 — Resistant Potato Starch to Alleviate GWI · Phase 2 · recruiting
NCT05367245 — Ca-Mg Butyrate in GWI · Phase 2 · recruiting
NCT05972291 — Mechanisms of Gulf War Illness · NA · recruiting
NCT05375812 — NIH Investigative Deep Phenotyping Study of Gulf War Veteran Health (Project NIH IN-DEPTH) · recruiting
NCT05675878 — Confirmation of Diet as a Treatment for Gulf War Illness · Phase 3 · recruiting

Other VISN 17 Center of Excellence trials

Trials by the same sponsor.

NCT02957747 — Addressing the Health Concerns of VA Women With Sexual Trauma · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03665740 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by VISN 17 Center of Excellence
Last refreshed: 11 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03665740.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing